

## 2009 revenues: +9.4%

|                                 |        |        |        | hange in constant |
|---------------------------------|--------|--------|--------|-------------------|
| In € million                    | 2008   | 2009   | Change | currencies        |
| First quarter                   | 24.0   | 27.5   | +14.8% | +5.2%             |
| Second quarter                  | 24.1   | 26.9   | +11.3% | +2.2%             |
| Third quarter                   | 22.0   | 22.9   | +3.9%  | -1.4%             |
| Fourth quarter                  | 23.0   | 24.6   | +7.1%  | +15.7%            |
| 12 months                       | 93.2   | 101.9  | +9.4%  | +5.5%             |
| Average US dollar exchange rate | 1.4757 | 1.3876 |        |                   |

Avignon - January 28, 2010. Driven by sustained demand for natural products and ingredients and despite a difficult economic backdrop, Naturex once again proved its ability to generate rapid organic growth in 2009. Consolidated revenues for the year amounted to € 101.9 million, up 9.4% on 2008. At constant scope and in constant currencies, yearly sales for the Group increased 5.5% in line with the ambitious growth target set at the start of the financial year.

In 2009, Nutrition & Health accounted for 64.7% of activity, Food & Beverage for 29.1% and Personal Care for 1.5%. Sales by geographical region broke down as follows: 59.8% for North America, 30.4% for the European Union and 3.2% for the Asia/Pacific region.

Naturex's growth prospects have been further enhanced by the integration of the Ingredients division of Natraceutical Group, which was approved by the Annual General Meeting of December 30, 2009. The consolidation of the revenues of the Group's new subsidiaries from January 1, 2010, will allow for a better balance in sales, both by geographical region and by sector of activity. As a result of the operation, Naturex now ranks as the global leader in specialty plant-based natural ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

In accordance with the terms and conditions of the contribution agreement, the final acquisition price will be determined in April 2010. Naturex will therefore publish its results (consolidated and proforma) for financial year 2009 on April 30. Bolstered by its strong commercial performance, the Group has confirmed its target improvement in operating margin.

Naturex will publish its yearly results and proforma financial statements for 2009 on April 30 after the close of trading, and will present them to the financial community on Monday 3 May.

If you would like to receive financial information about Naturex by e-mail, register at: www.actus-finance.com

NATUREX has been listed on Euronext Paris since October 1996 (segment B).

Number of shares: 6,364,000 (4,843,597 ordinary shares and 1,520,403 preferential shares).

ISIN: FR0000054694 – Reuters: NATU.PA – Bloomberg: NRX:FP.

www.naturex.com



## About Naturex:

Following the integration of the Ingredients division of Natraceutical Group which was approved by the Annual General Meeting of December 30, 2009, Naturex now ranks as the global leader in specialty plant-based natural ingredients. Naturex manufactures and markets natural ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries. The Group has three strategic divisions: Food & Beverage, Nutrition & Heath and Personal Care.

Naturex's sound performance is linked to the fast-growing demand for natural ingredients and its capacity to provide manufacturers with the means to meet the requirements of their end consumers. Its strength lies in its ability to position itself on specific products which constitute market niches.

Based in Avignon, the Group employs around 900 people and realizes over 90% of its sales overseas. Naturex has production units across Europe (France, Italy, Spain, the United Kingdom and Switzerland) as well as in Morocco, the United States, Brazil and Australia. It also has 9 sales offices located in Europe, the United States and Asia.

| Naturex contacts:         | Actus contacts:            |  |  |
|---------------------------|----------------------------|--|--|
| Jacques Dikansky,         | Laurence Marquézy,         |  |  |
| President and CEO         | Investor Relations         |  |  |
|                           |                            |  |  |
| Tel: +33 (0)4 90 23 96 89 | Tel: + 33 (0)1 72 74 82 23 |  |  |
| naturex@naturex.com       | lmarquezy@actus.fr         |  |  |
| Thierry Lambert,          | Anne Catherine Bonjour,    |  |  |
| Vice-President and CFO    | Press Relations            |  |  |
| Tel: +33 (0)4 90 23 96 89 | Tel: + 33 (0)1 53 67 36 93 |  |  |
| t.lambert@naturex.com     | acbonjour@actus.fr         |  |  |